Summary & Overview
HCPCS Level II J0598: C1 Esterase Inhibitor (Cinryze), 10 Units
HCPCS Level II code J0598 designates an injectable dose of C1 esterase inhibitor (human), branded as Cinryze, measured per 10 units. Nationally, this code is central to billing for replacement therapy for hereditary angioedema patients receiving prophylactic or acute treatment with a plasma-derived biologic. Accurate coding affects coverage determinations, site-of-care billing, and reimbursement for high-cost specialty therapies.
Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for J0598, payer coverage considerations, and typical service settings. The publication summarizes benchmark metrics where available, highlights relevant policy and prior authorization trends from major payers, and explains billing nuances for infusion-based biologic administration.
This resource is intended for billing managers, clinical coders, pharmacy and infusion administrators, and policy analysts seeking concise, actionable information about HCPCS Level II code J0598, its clinical application, and the payer environment surrounding high-cost injectable biologics.
Billing Code Overview
HCPCS Level II code J0598 represents an injection of C1 esterase inhibitor (human), Cinryze, 10 units. This code denotes a therapeutic biologic used for replacement therapy in patients with hereditary angioedema to prevent or treat acute attacks.
-
Service type: Injectable biologic therapy
-
Typical site of service: Infusion center, outpatient clinic, or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with hereditary angioedema (HAE) presenting for prophylactic or on-demand intravenous replacement of C1 esterase inhibitor (human) using cinryze. The patient arrives to an outpatient infusion center or hospital outpatient department with an order for J0598 (cinryze, 10 units). Pre-infusion workflow includes verification of identity and insurance, review of medication history and HAE attack frequency, baseline vital signs, and assessment for recent infections or hypersensitivity. An intravenous line is placed by a registered nurse or licensed infusion clinician. The dose is calculated based on the prescribing provider's order (commonly 1000 units intravenously for adults, administered as multiple vials billed as J0598 per 10 units). The nurse prepares the product per manufacturer instructions, performs infection control checks, and administers the infusion while monitoring for infusion reaction, anaphylaxis, or local IV complications. Post-infusion monitoring includes observation for adverse reactions, documentation of lot number and units administered, and discharge instructions. Billing staff append appropriate modifiers to J0598 to indicate service details (for example, facility vs professional billing, discontinued services, or split/shared services). Typical sites of service are outpatient infusion centers, hospital outpatient departments, emergency departments for acute treatment, and occasionally home infusion under specialty pharmacy and home health oversight.
Coding Specifications
| Modifier | Description | When to Use |
|---|